Privium Fund Management B.V. Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Privium Fund Management B.V. reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 22.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 62,232 shares of the company’s stock after selling 18,000 shares during the period. Axsome Therapeutics makes up approximately 1.2% of Privium Fund Management B.V.’s portfolio, making the stock its 18th biggest holding. Privium Fund Management B.V. owned 0.13% of Axsome Therapeutics worth $5,265,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Assetmark Inc. acquired a new stake in Axsome Therapeutics during the fourth quarter worth about $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $64,000. KBC Group NV increased its holdings in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares in the last quarter. Moors & Cabot Inc. purchased a new position in shares of Axsome Therapeutics during the 3rd quarter valued at approximately $200,000. Finally, Xponance Inc. boosted its holdings in Axsome Therapeutics by 11.6% during the fourth quarter. Xponance Inc. now owns 2,659 shares of the company’s stock worth $225,000 after buying an additional 277 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 22.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Morgan Stanley upped their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Axsome Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $176.00 price target for the company. Bank of America raised their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Truist Financial upped their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, Royal Bank of Canada lifted their price target on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $167.36.

Axsome Therapeutics Stock Down 0.7 %

AXSM stock opened at $124.76 on Wednesday. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The firm has a 50-day moving average of $113.88 and a two-hundred day moving average of $99.47. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The company has a market cap of $6.08 billion, a price-to-earnings ratio of -20.83 and a beta of 0.99.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. As a group, analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.